The COVID-19 pandemic is causing betas and other measures of risk commonly used in company valuations to appear to have changed. Beta is a critical component used by valuation experts when determining the discount rate in business valuation. Even small changes in betas can cause large changes in the discount rate and, consequently, can cause large changes in valuation. In this panel discussion, Dr. Roper and Cliff Ang, CFA, will describe how the COVID-19 pandemic is impacting the data valuation experts rely on to assess risk when performing business valuations and whether practitioners should incorporate this change in their business valuations. Audience participants will learn about new research and available data that they may need to consider when determining whether the COVID-19 pandemic is impacting company valuations because of changes in risk.